Last updated on January 2017

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes


Brief description of study

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

Detailed Study Description

This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes. In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks. In Metformin treatment group, 88 subjects will be assigned and the subjects administer Metformin for 16 weeks. In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer Rosuvastatin for 16 weeks.

Clinical Study Identifier: NCT02586129

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Hakcheol Jang, M.D., Ph.D

Seoul National Universitiy Bundang Hospital
Seongnam-Si, Korea, Republic of
  Connect »